Chi2gel
Hybrid Hydrogels for Orthopedics and Rheumatology
Health Tech & Life Sciences
Non Active, May 2019 ceased to operate
Company Overview
Snapshot
Founded in July 2008, Chi2gel operated with 1–10 employees. The company secured $658,000 across one funding round from one investor. Chi2gel ceased operations in May 2019.
Business overview
Chi2gel was a development-stage company focused on creating hydrogel-based devices for orthopedics and rheumatology. Its proprietary hybrid hydrogel technology was designed to revitalize degenerated spinal discs and treat painful knee osteoarthritis. The company's product pipeline included Chi2Knee for intra-articular injection as a viscosupplement and Chi2Disc for degenerative disc disease, operating within the Health Tech & Life Sciences sector.
Company Intelligence Q&A
- What was Chi2gel's primary focus?
- Chi2gel focused on developing hybrid hydrogels for applications in orthopedics and rheumatology, specifically targeting conditions like degenerated spinal discs and knee osteoarthritis.
- When was Chi2gel founded?
- Chi2gel was founded in July 2008.
- What was the status of Chi2gel's operations?
- Chi2gel ceased to operate in May 2019.
- What was the total capital raised by Chi2gel?
- Chi2gel raised a total of $658,000.
- What products was Chi2gel developing?
- Chi2gel was developing Chi2Knee for knee osteoarthritis and Chi2Disc for lower back pain related to degenerative disc disease, both based on its proprietary hydrogel technology.